- Your selection
- Clear all
- Pharmaceuticals x
- Europe x
- With Teaching Note x
10 cases found.
Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
- By
Reference 6031
Published 27 Jan 2014
Region Europe
Industry Pharmaceuticals
Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
- By
Reference 6031
Published 27 Jan 2014
Region Europe
Industry Pharmaceuticals
Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient 10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.
- By
Reference 5381
Published 07 Jan 2006
Topic Marketing
Region Europe
Industry Pharmaceuticals
NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient 10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.
In July 1996, the French social security governmental agency (the CNAM) sent a letter to all doctors urging them to prescribe generic amoxicillin instead of Clamoxyl, SmithKline Beechams (SB) blockbuster antibiotic.
- By
Reference 5057
Published 01 Jun 2003
Topic Marketing
Region Europe
Industry Pharmaceuticals
In July 1996, the French social security governmental agency (the CNAM) sent a letter to all doctors urging them to prescribe generic amoxicillin instead of Clamoxyl, SmithKline Beechams (SB) blockbuster antibiotic.
The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should followed?
- By
Reference 5057
Published 06 Jan 2003
Topic Marketing
Region Europe
Industry Pharmaceuticals
The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should followed?
The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.
- By
Reference 4927
Published 01 Dec 2000
Topic Economics & Finance
Region Europe
Industry Pharmaceuticals
The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.
In September 1990, the financial controller of the Italian subsidiary of Glaxo must evaluate a financial analysis comparing two marketing strategies for introducing a new antibiotic into the Italian market. The task for the student is to evaluate and correct the discounted cash flow analysis.
- By
Reference 4386
Published 01 Jan 1992
Topic Economics & Finance
Region Europe
Industry Pharmaceuticals
In September 1990, the financial controller of the Italian subsidiary of Glaxo must evaluate a financial analysis comparing two marketing strategies for introducing a new antibiotic into the Italian market. The task for the student is to evaluate and correct the discounted cash flow analysis.
Business has traditionally enjoyed a pre-eminent position in the Swiss political economy. This case looks at political conflicts over chemicals and biotechnology regulation and Swiss entry into the European Economic Area, showing how the growing environmentalist movements have challenged this position and that important changes in the Swiss political economy may be imminent.
- By
Reference 4222
Published 01 Jan 1993
Topic Economics & Finance
Region Europe
Industry Pharmaceuticals, Biotechnology, Chemicals
Business has traditionally enjoyed a pre-eminent position in the Swiss political economy. This case looks at political conflicts over chemicals and biotechnology regulation and Swiss entry into the European Economic Area, showing how the growing environmentalist movements have challenged this position and that important changes in the Swiss political economy may be imminent.
The cases describe the development, worldwide launch, and subsequent marketing of a new pharmaceutical product which, although it represented only a slight improvement over the category pioneer, not only became the leading product in its category, but the largest prescription pharmaceutical product overall worldwide.
- By
Reference 236
Published 09 Jan 1992
Topic Marketing
Region Europe
Industry Pharmaceuticals
The cases describe the development, worldwide launch, and subsequent marketing of a new pharmaceutical product which, although it represented only a slight improvement over the category pioneer, not only became the leading product in its category, but the largest prescription pharmaceutical product overall worldwide.
The cases describe the development, worldwide launch, and subsequent marketing of a new pharmaceutical product which, although it represented only a slight improvement over the category pioneer, not only became the leading product in its category, but the largest prescription pharmaceutical product overall worldwide.
- By
Reference 236
Published 01 Jan 1993
Topic Marketing
Region Europe
Industry Pharmaceuticals
The cases describe the development, worldwide launch, and subsequent marketing of a new pharmaceutical product which, although it represented only a slight improvement over the category pioneer, not only became the leading product in its category, but the largest prescription pharmaceutical product overall worldwide.